Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients

[1]  Z. Zhan,et al.  Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo. , 2015, Genetics and molecular research : GMR.

[2]  T. Keil,et al.  Innate IgG Molecules and Innate B Cells Expressed by Immunoglobulin Constant Heavy G Chain (Fcγ) Genetic Marker Genes Are Involved in the ‘Allergic March' of IgE Sensitization in Children , 2015, International Archives of Allergy and Immunology.

[3]  Fengchun Zhang,et al.  Serum IgG Subclasses in Autoimmune Diseases , 2015, Medicine.

[4]  Vikram Deshpande,et al.  The diagnostic utility of serum IgG4 concentrations in IgG4-related disease , 2014, Annals of the rheumatic diseases.

[5]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[6]  G. Vidarsson,et al.  IgG-effector functions: "the good, the bad and the ugly". , 2014, Immunology letters.

[7]  P. Dalby,et al.  The Fab Conformations in the Solution Structure of Human Immunoglobulin G4 (IgG4) Restrict Access to Its Fc Region , 2014, The Journal of Biological Chemistry.

[8]  M. Picardo,et al.  Guidelines for the management of vitiligo: the European Dermatology Forum consensus , 2013, The British journal of dermatology.

[9]  K. Alghamdi,et al.  Assessment methods for the evaluation of vitiligo , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  T. Lotti,et al.  Multidisciplinary approach to R&D in vitiligo, a neglected skin disease , 2012, Dermatologic therapy.

[11]  D. Gawkrodger,et al.  Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients , 2012, The British journal of dermatology.

[12]  C. Pirovani,et al.  Analysis of IgG subclasses (IgG1 and IgG3) to recombinant SAG2A protein from Toxoplasma gondii in sequential serum samples from patients with toxoplasmosis. , 2012, Immunology letters.

[13]  Jinming Li,et al.  Preferentially immunoglobulin (IgG) subclasses production in primary Sjögren’s syndrome patients , 2012, Clinical chemistry and laboratory medicine.

[14]  B. Haynes,et al.  Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection , 2011, AIDS.

[15]  Jinming Li,et al.  Evaluation of Serum IgG Subclass Concentrations in Myasthenia Gravis Patients , 2011, The International journal of neuroscience.

[16]  Meaghan Daly,et al.  Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. , 2011, Journal of the American Academy of Dermatology.

[17]  Ji Young Kim,et al.  Detection of melanocyte autoantigens reacting with autoantibodies in vitiligo patients by proteomics. , 2011, Journal of dermatological science.

[18]  A. Ökten,et al.  Relevance of autoimmune thyroiditis in children and adolescents with vitiligo , 2011, International journal of dermatology.

[19]  D. Gawkrodger,et al.  Autoantibodies against tyrosine hydroxylase in patients with non‐segmental (generalised) vitiligo , 2011, Experimental dermatology.

[20]  L. Naldi,et al.  Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  H. Hakonarson,et al.  The genetics of asthma and allergic disorders. , 2011, Discovery medicine.

[22]  A. Kawada,et al.  Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. , 2011, Allergology international : official journal of the Japanese Society of Allergology.

[23]  A. Farboud,et al.  Serological investigation of IgG levels and subclasses in rheumatoid arthritis patients following ingestion of bovine type II collagen: results of a double blind, randomised controlled trial , 2011, Clinical Rheumatology.

[24]  Jinming Li,et al.  Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis , 2011, Clinical Rheumatology.

[25]  C. Libert,et al.  The X chromosome in immune functions: when a chromosome makes the difference , 2010, Nature Reviews Immunology.

[26]  W. Bari,et al.  Immunoglobulin levels of vitiligo patients. , 2010, Pakistan journal of pharmaceutical sciences.

[27]  G. Lin,et al.  Elevation of serum IgG subclass concentration in patients with rheumatoid arthritis , 2010, Rheumatology International.

[28]  M. Taguchi,et al.  Decreased production of immunoglobulin M and A in autoimmune pancreatitis , 2009, Journal of Gastroenterology.

[29]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[30]  T. Rispens,et al.  Immunoglobulin G4: an odd antibody , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[31]  G. Landman,et al.  Vitiligo: analysis of grafting versus curettage alone, using melanocyte morphology and reverse transcriptase polymerase chain reaction for tyrosinase mRNA. , 2005, Sao Paulo medical journal = Revista paulista de medicina.

[32]  Mohammad Z Zailaie.  Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients. , 2005, Saudi Medical Journal.

[33]  J. Ortonne,et al.  Physiopathology and genetics of vitiligo. , 2005, Journal of autoimmunity.

[34]  Dennis R. Burton,et al.  Human antibody–Fc receptor interactions illuminated by crystal structures , 2004, Nature Reviews Immunology.

[35]  W. D. Geoghegan,et al.  Bullous pemphigoid autoantibodies reactive with intracellular basal keratinocyte antigens: Studies of subclass distribution and complement activation , 1992, Journal of Clinical Immunology.

[36]  J. Naeyaert,et al.  Evidence for an autoimmune pathogenesis of vitiligo. , 2003, Pigment cell research.

[37]  W. Westerhof,et al.  Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. , 1999, Archives of dermatology.

[38]  A. Houghton,et al.  A melanosomal membrane protein is a cell surface target for melanoma therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  C. Yu,et al.  Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. , 1993, The Journal of investigative dermatology.

[40]  J. Bystryn,et al.  Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. , 1991, The Journal of investigative dermatology.

[41]  J. Bystryn,et al.  Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. , 1988, The Journal of investigative dermatology.